Results 201 to 210 of about 25,171,962 (340)

Validating Single-Step Genomic Predictions for Growth Rate and Disease Resistance in <i>Eucalyptus globulus</i> with Metafounders. [PDF]

Genes (Basel)
Gonzalez M, Aguilar I, Bermann M, Quezada M, Hidalgo J, Misztal I, Lourenco D, Balmelli G.   +7 more
europepmc   +1 more source

A feature selection model based on genetic rank aggregation for text sentiment classification

Journal of information science, 2017
Aytuğ Onan, S. Korukoglu
semanticscholar   +1 more source

Evaluation of KRAS and NRAS mutations in metastatic colorectal cancer: an 8‐year study of 10 754 patients in Turkey

Molecular Oncology, EarlyView.
This nationwide study evaluated KRAS and NRAS mutations in 10 754 Turkish patients with metastatic colorectal cancer. The results revealed a mutation frequency of 51.1%, with 46.6% having KRAS mutations, 4.5% having NRAS mutations, and 48.5% being wild‐type for both.
Gozde Kavgaci, Izzet Akiva, Yavuz Hakan Ozon, Hakan Berkil, Huseyin Karadayi, Omer Dizdar, Suayib Yalcin   +6 more
wiley   +1 more source

Beyond additive genetic effects: Explaining family resemblance in school performance across millions of pairs of Norwegian relatives. [PDF]

Proc Natl Acad Sci U S A
Eftedal NH, Eilertsen EM, Sunde HF, Kleppestø TH, Ystrom E, Czajkowski NO.   +5 more
europepmc   +1 more source

Landscape of BRAF transcript variants in human cancer

Molecular Oncology, EarlyView.
We investigate the annotation of BRAF variants, focusing on protein‐coding BRAF‐220 (formerly BRAF‐reference) and BRAF‐204 (BRAF‐X1). The IsoWorm pipeline allows us to quantify these variants in human cancer, starting from RNA‐sequencing data. BRAF‐204 is more abundant than BRAF‐220 and impacts patient survival.
Maurizio S. Podda, Danilo Tatoni, Gianluca Mattei, Alberto Magi, Romina D'Aurizio, Laura Poliseno   +5 more
wiley   +1 more source

Fractional-order SIR model for ADHD as a neurobiological and genetic disorder. [PDF]

Sci Rep
Afzal Z, Alshehri M.
europepmc   +1 more source

Loss of proton‐sensing GPR4 reduces tumor progression in mouse models of colon cancer

Molecular Oncology, EarlyView.
G protein‐coupled receptor 4 (GPR4) is a pH‐sensing receptor activated by acidic pH. GPR4 expression is increased in patients with inflammatory bowel disease who are at high risk of developing colorectal cancer. In mouse models, loss of GPR4 attenuated tumor progression. This correlated with increased IL2 and natural killer cell activity.
Leonie Perren, Moana Busch, Pedro A. Ruiz, Ermanno Malagola, Valeria Baumeler, Federica Foti, Adelina Gross, Tobias Grütter, Hendrik Edel, Cordelia Schuler, Kristina Handler, Glenn De Lange, Isabelle C. Arnold, Cheryl de Vallière, Klaus Seuwen, Martin Hausmann, Gerhard Rogler   +16 more
wiley   +1 more source

Preclinical models of mitochondrial dysfunction: mtDNA and nuclear-encoded regulators in diverse pathologies. [PDF]

Front Aging
Miller DM, Archer SL, Dunham-Snary KJ.
europepmc   +1 more source

TRPM8 levels determine tumor vulnerability to channel agonists

Molecular Oncology, EarlyView.
TRPM8 is a Ca2+ permissive channel. Regardless of the amount of its transcript, high levels of TRPM8 protein mark different tumors, including prostate, breast, colorectal, and lung carcinomas. Targeting TRPM8 with channel agonists stimulates inward calcium currents followed by emptying of cytosolic Ca2+ stores in cancer cells.
Alessandro Alaimo, Francesco Giuseppe Carbone, Kristi Buzo, Nicole Annesi, Sacha Genovesi, Annalisa Lorenzato, Karen Widmann, Michela Libergoli, Elisa Marmocchi, Giovanni Bertalot, Alberto Brolese, Mauro Giulio Papotti, Luca Molinaro, Orazio Caffo, Mattia Barbareschi, Alberto Bardelli, Alessandro Romanel, Sabrina Arena, Andrea Lunardi   +18 more
wiley   +1 more source

Improving polygenic prediction from whole-genome sequencing data by leveraging predicted epigenomic features. [PDF]

Proc Natl Acad Sci U S A
Zeng W, Guo H, Liu Q, Wong WH.
europepmc   +1 more source